Takeshi Yoshida

Takeshi Yoshida

Auto-generated profile, based on publicly available information

Takeshi Yoshida

Department of Molecular Virology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NSNaoto Suzuki
Naoto Suzuki
TYTakeshi Yoshida
Takeshi Yoshida
HTHiroaki Takeuchi
Hiroaki Takeuchi
RSRyuta Sakuma
Ryuta Sakuma
SSSayaka Sukegawa
Sayaka Sukegawa
SYShoji Yamaoka
Shoji Yamaoka
Lentiviral vectors are a valuable tool to deliver exogenous genes for stable expression in cells. While much progress has been made in processing lentiviral vector-containing culture medium, it remains to be explored how the production of lentiviral vector from producer cells can be increased. We initially found that co-expression of the SPRY domain-containing SOCS box protein 1 (SPSB1) promotes the production of human immunodeficiency virus type 1 (HIV-1) and lentiviral vector with increased expression of the Gag and envelope proteins and activation of the HIV-1 LTR and CMV promoter. The presence of AP-1, NF-κB and CREB/ATF recognition sites in these promoters prompted us to utilize human T-lymphotropic virus type 1 (HTLV-1) Tax for lentiviral vector production because Tax activates all these transcription factors. Co-expression of a small amount of Tax markedly increased both the expression of viral structural proteins in producer cells and release of lentiviral vector particles, resulting in a more than 10-fold enhancement of transduction efficiency. Of note, the Tax protein was not detected in the lentiviral vector particles concentrated by ultracentrifugation, supporting the safety of this preparation. Collectively, these results indicate that promoter activation in producer cells represents a promising approach to preparing high-titer lentiviral vectors.

20 February 2024 in Journal of Virology
Verified
Journal Article
Closed access
TYTakeshi Yoshida
Takeshi Yoshida
YKYuho Kasuya
Yuho Kasuya
HYHiroyuki Yamamoto
Hiroyuki Yamamoto
GKGota Kawai
Gota Kawai
KHKen-Ichi Hanaki
Ken-Ichi Hanaki
TMTakao Masuda
Takao Masuda
Since the promoter for transcribing HIV-1 RNA is unique, all viral elements including genomic RNA and viral proteins have to be generated by the unique transcripts through ingenious mechanisms including RNA splicing and frameshifting during protein translation. Previous studies suggested a new mechanism for diversification of HIV-1 RNA functions by heterogeneous transcriptional initiation site usage; HIV-1 RNAs whose transcription initiates from a certain nucleotide were predominant in virus particles. In this study, we established two methods to analyze heterogenous transcriptional initiation site usage by HIV-1 during viral infection and showed that RNAs beginning with one guanosine (G1-form RNAs), whose transcription initiates from the third deoxyguanosine of the GGG tract in 5′ LTR, were primarily selected as viral genome in infectious particles and thus are used as a template to generate provirus for continuous replication. This study provides insights into the mechanism for diversification of unspliced RNA functions and requisites of lentivirus infectivity.

1 December 2021 in Frontiers in Microbiology
Verified
Journal Article
Open access
LSLuca Sardo
Luca Sardo
CPCristina Parolin
Cristina Parolin
TYTakeshi Yoshida
Takeshi Yoshida
AGAlfredo Garzino-Demo
Alfredo Garzino-Demo
Taisuke IzumiTaisuke Izumi
Taisuke Izumi
Editorial: Novel Insights Into a Functional HIV Cure

23 February 2022 in Journal of Virology
Verified
Journal Article
Closed access
WYWeitong Yao
Weitong Yao
KSKlaus Strebel
Klaus Strebel
SYShoji Yamaoka
Shoji Yamaoka
TYTakeshi Yoshida
Takeshi Yoshida
Genes related to survival against life-threating pathogens are important determinants of natural selection in animal evolution. For instance, BST-2, a protein showing broad-spectrum antiviral activity, shows polymorphisms entailing different phenotypes even among primate species, suggesting that the bst-2 gene of primates has been subject to strong selective pressure during evolution.

1 June 2019 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
IAIshmael Dzigbordi Aziati
Ishmael Dzigbordi Aziati
TYTakeshi Yoshida
Takeshi Yoshida
AHAkiko Hamano
Akiko Hamano
KMKenjiro Maeda
Kenjiro Maeda
HTHiroaki Takeuchi
Hiroaki Takeuchi
SYShoji Yamaoka
Shoji Yamaoka

6 January 2020 in Journal of Virology
Verified
Journal Article
Closed access
WYWeitong Yao
Weitong Yao
TYTakeshi Yoshida
Takeshi Yoshida
SHSaki Hashimoto
Saki Hashimoto
HTHiroaki Takeuchi
Hiroaki Takeuchi
KSKlaus Strebel
Klaus Strebel
SYShoji Yamaoka
Shoji Yamaoka
Genetic alterations conferring a selective advantage in protecting from life-threating pathogens are maintained during evolution. In fact, the amino acid sequences of BST-2 differ among primate animals and their susceptibility to viral proteins is species specific, suggesting that such genetic diversity has arisen through the evolutionarily controlled balance between the host and pathogens. The M (main) group of HIV-1 is thought to be derived from SIVcpz, which utilizes Nef, but not Vpu, to antagonize chimpanzee BST-2. SIVcpz Nef is, however, unable to antagonize human BST-2, and Vpu was consequently chosen again as an antagonist against human BST-2 in the context of HIV-1. Studies on how Vpu lost and acquired this ability, together with the distinct mechanisms by which SIVgsn71 Vpu binds to and downregulates human or GSN BST-2, may help to explain the evolution of this lentiviral protein as a result of host-pathogen interactions.